vTv Therapeutics, Inc. Class A VTVT 深 滬
已收盤 04-02 16:00:00 美东时间
41.17
+0.640
+1.58%
華盛通- 最 高43.09
- 今 開40.16
- 成交量 4.10万股
- 最 低 40.16
- 昨 收 40.53
- 總市值 1.62亿
- 52周最高 44.00
- 市盈率 靜 --
- 換手率 1.04%
- 52周最低 14.00
- 委 比 0.00%
- 總股本 393.89万
- 歷史最高 560.00
- 量 比 1.23
- 振 幅 7.23%
- 歷史最低 7.38
- 每 手 1
- 風險率 8.57%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 潜在涨幅101%！甲骨文获花旗升目标价至320美元，维持"买入"评级
今日重点评级关注：Freedom Capital Markets：维持LifeMD"买入"评级，目标价从8美元升至10美元；Chardan Capital：维持Opus Genetics"买入"评级，目标价从9美元升至11美元
03-13 09:59
This Jabil Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Top Wall Street analysts changed outlook on certain stocks. See analyst ratings and advice on Rush Street, Jabil, Enovix, Planet Fitness, and vTv Therapeutics.
03-12 20:16
美股大行评级 | 甲骨文绩后分歧大！小摩上调评级至"超配"，目标价缺降至210美元；科尔士百货、AVAV、Blend Labs、Domo遭多家大行下调评级
今日重点评级关注：LUCID CAPITAL MARKETS：上调INmune Bio评级至"买入" 目标价从2美元升至9美元；Clear Street：维持MoonLake Immunotherapeutics Class A"买入"评级，目标价从45美元升至70美元
03-12 12:34
BTIG Reiterates Buy on vTv Therapeutics, Maintains $49 Price Target
BTIG analyst Kambiz Yazdi reiterates vTv Therapeutics (NASDAQ:VTVT) with a Buy and maintains $49 price target.
03-12 01:25
vTv Therapeutics Q4 EPS $(0.58) Beats $(1.17) Estimate
vTv Therapeutics (NASDAQ:VTVT) reported quarterly losses of $(0.58) per share which beat the analyst consensus estimate of $(1.17) by 50.21 percent. This is a 5.45 percent decrease over losses of $(0.55) per share from
03-11 04:03
vTvT posts Q2 net loss of USD 6.0 million (USD 0.92 per share)
vTvT posts Q2 net loss of USD 6.0 million (USD 0.92 per share) vTvT reported Q2 2025 results with a net loss attributable to shareholders of USD 6.0 million and a net loss per basic share of USD 0.92. R&D expenses were USD 4.1 million and G&A expenses were USD 3.6 million for the quarter. Cash and c
03-06 21:50
vTv Therapeutics Highlights Cadisegliatin Progress and Financial Strength
vTv Therapeutics ( ($VTVT) ) just unveiled an update. On February 26, 2026, vTv...
02-26 21:19
vTv Therapeutics Presents at TD Cowen Health Care Conference
vTv Therapeutics Presents at TD Cowen Health Care Conference vTv Therapeutics Inc. will participate in the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3, 2026, at 9:50 AM ET. The event, held in Boston, MA, will feature a presentation and 1x1 meetings. A webcast link for the event i
02-13 21:00
vTv Therapeutics to Participate in Upcoming Investor Conferences
vTv Therapeutics announced that its management will participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26, 2026, and the TD Cowen 46th Annual Health Care Conference on March 3, 2026. The company is focused on developing cadisegliatin, a potential first-in-class oral therapy for type 1 diabetes, currently in a US Phase 3 trial. **Contact:** **Investor:** John Fraunces, jfraunces@lifesciadvisors.com **Me...
02-13 13:00
